Anjarium Biosciences AG, a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies, closed a CHF55.5M ($61M) Series A financing.
The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). In conjunction with Anjarium’s Series A financing, Dr. Bali Muralidhar of Abingworth, Dr. Bram Vanparys of Gimv and Dr. Dina Chaya of Omega Funds will join the company’s Board of Directors.
The company intends to use the funds to expand its team, advance its platform and progress several therapeutic pipeline programs towards clinical development.
Led by Joël de Beer, Founder and CSO, Anjarium Biosciences leverages a platform at the interface of genetic medicine, synthetic biology and nanoparticle engineering to to rationally design and produce tissue-targeted gene therapies, optimized to improve patient outcomes in a range of serious genetic diseases.
The company’s platform combines proprietary DNA-based gene vectors, natural and synthetic nanoparticle delivery modalities – including its novel Hybridosome™ technology – and scalable manufacturing solutions.